In silico characterisation of putative Plasmodium falciparum vaccine candidates in African malaria populations

被引:0
|
作者
O. Ajibola
M. F. Diop
A. Ghansah
L. Amenga-Etego
L. Golassa
T. Apinjoh
M. Randrianarivelojosia
O. Maiga-Ascofare
W. Yavo
M. Bouyou-Akotet
K. M. Oyebola
B. Andagalu
U. D’Alessandro
D. Ishengoma
A. A. Djimde
E. Kamau
A. Amambua-Ngwa
机构
[1] The Gambia at London School of Hygiene and Tropical Medicine,Medical Research Council Unit
[2] First Technical University,Noguchi Memorial Institute for Medical Research
[3] University of Ghana,West African Center for Cell Biology of Infectious Pathogens
[4] University of Ghana,Aklilu Lemma Institute of Pathobiology
[5] Addis Ababa University,Department of Biochemistry and Molecular Biology
[6] University of Buea,Unite Des Sciences Pharmaceutiques et Biologiques
[7] Institut Pasteur of Madagascar,Faculty of Medicine
[8] Bernhard Nocht Institute for Topical Medicine (BNITM),Department of Zoology
[9] University Félix Houphouët-Boigny,United States Army Medical Research Directorate
[10] University of Health Sciences,Africa
[11] University of Lagos,Malaria Research and Training Centre
[12] Kenya Medical Research Institute/Walter Reed Project,Department of Pathology and Laboratory Medicine, David Geffen School of Medicine
[13] National Institute for Medical Research (NIMR),U.S. Military HIV Research Program
[14] University of Science,undefined
[15] Techniques and Technologies of Bamako,undefined
[16] University of California,undefined
[17] Walter Reed Army Institute of Research,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Genetic diversity of surface exposed and stage specific Plasmodium falciparum immunogenic proteins pose a major roadblock to developing an effective malaria vaccine with broad and long-lasting immunity. We conducted a prospective genetic analysis of candidate antigens (msp1, ama1, rh5, eba175, glurp, celtos, csp, lsa3, Pfsea, trap, conserved chrom3, hyp9, hyp10, phistb, surfin8.2, and surfin14.1) for malaria vaccine development on 2375 P. falciparum sequences from 16 African countries. We described signatures of balancing selection inferred from positive values of Tajima’s D for all antigens across all populations except for glurp. This could be as a result of immune selection on these antigens as positive Tajima’s D values mapped to regions with putative immune epitopes. A less diverse phistb antigen was characterised with a transmembrane domain, glycophosphatidyl anchors between the N and C- terminals, and surface epitopes that could be targets of immune recognition. This study demonstrates the value of population genetic and immunoinformatic analysis for identifying and characterising new putative vaccine candidates towards improving strain transcending immunity, and vaccine efficacy across all endemic populations.
引用
收藏
相关论文
共 50 条
  • [31] Structure of the Plasmodium falciparum Circumsporozoite Protein, a Leading Malaria Vaccine Candidate
    Plassmeyer, Matthew L.
    Reiter, Karine
    Shimp, Richard L., Jr.
    Kotova, Svetlana
    Smith, Paul D.
    Hurt, Darrell E.
    House, Brent
    Zou, Xiaoyan
    Zhang, Yanling
    Hickman, Merrit
    Uchime, Onyinyechukwu
    Herrera, Raul
    Nguyen, Vu
    Glen, Jacqueline
    Lebowitz, Jacob
    Jin, Albert J.
    Miller, Louis H.
    MacDonald, Nicholas J.
    Wu, Yimin
    Narum, David L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (39) : 26951 - 26963
  • [32] RATIONALE FOR DEVELOPMENT OF A SYNTHETIC VACCINE AGAINST PLASMODIUM-FALCIPARUM MALARIA
    ZAVALA, F
    TAM, JP
    HOLLINGDALE, MR
    COCHRANE, AH
    QUAKYI, I
    NUSSENZWEIG, RS
    NUSSENZWEIG, V
    SCIENCE, 1985, 228 (4706) : 1436 - 1440
  • [33] VARIATION IN THE CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM FALCIPARUM: IMPLICATIONS FOR MALARIA VACCINE DEVELOPMENT
    Gandhi, Kavita
    Thera, Mahamadou A.
    Coulibaly, Drissa
    Traore, Karim
    Doumbo, Ogobara K.
    Takala-Harrison, Shannon
    Plowe, Christopher V.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 172 - 172
  • [34] A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum
    Druilhe, P
    Spertini, F
    Soesoe, D
    Corradin, G
    Mejia, P
    Singh, S
    Audran, R
    Bouzidi, A
    Oeuvray, C
    Roussilhon, C
    PLOS MEDICINE, 2005, 2 (11) : 1135 - 1144
  • [35] Elementary step in development vaccine against Plasmodium falciparum malaria in Iran
    Keshavarz, H.
    Heidari, A.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2009, 14 : 133 - 133
  • [36] Malaria vaccine development based on merozoite surface proteins of Plasmodium falciparum
    Chauhan, Virander S.
    Yazdani, Syed Shams
    Gaur, Deepak
    HUMAN VACCINES, 2010, 6 (09): : 757 - 762
  • [37] Antibodies to Plasmodium falciparum antigens and the risk of clinical malaria in endemic populations
    Koram, Kwadwo A.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2011, 9 (11) : 987 - 991
  • [38] SOLUBLE ANTIGENS IN BLOOD OF AFRICAN PATIENTS WITH SEVERE PLASMODIUM FALCIPARUM MALARIA
    MCGREGOR, IA
    TURNER, MW
    WILLIAMS, K
    HALL, P
    LANCET, 1968, 1 (7548): : 881 - &
  • [39] Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum
    Arnot, David E.
    Cavanagh, David R.
    Remarque, Edmond J.
    Creasey, Alison M.
    Sowa, Mercy P. K.
    Morgan, William D.
    Holder, Anthony A.
    Longacre, Shirley
    Thomas, Alan W.
    CLINICAL AND VACCINE IMMUNOLOGY, 2008, 15 (09) : 1345 - 1355
  • [40] Comparative Assessment of Transmission-Blocking Vaccine Candidates against Plasmodium falciparum
    Kapulu, M. C.
    Da, D. F.
    Miura, K.
    Li, Y.
    Blagborough, A. M.
    Churcher, T. S.
    Nikolaeva, D.
    Williams, A. R.
    Goodman, A. L.
    Sangare, I.
    Turner, A. V.
    Cottingham, M. G.
    Nicosia, A.
    Straschil, U.
    Tsuboi, T.
    Gilbert, S. C.
    Long, Carole A.
    Sinden, R. E.
    Draper, S. J.
    Hill, A. V. S.
    Cohuet, A.
    Biswas, S.
    SCIENTIFIC REPORTS, 2015, 5